BioCentury
ARTICLE | Finance

$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate

July 10, 2020 7:58 PM UTC

Stanford spinout Tranquis is the latest biotech looking to put the neuroinflammation theory to the test, raising $30 million Thursday in a series A to bring its first neurodegenerative disease candidate to the clinic next year.

Remiges Ventures and SR One co-led the tranched round, with participation from Vivo Capital, Hillsborough Venture, Correlation Ventures and other undisclosed investors...